Comprehensive Two-Dimensional Liquid Chromatography in Metabolome Analysis

Lucas Willmann1,3, Manuel Schlimpert1, Daqiang Pan1, Christoph Bauer1, Jens Trafkowski2, Sonja Krieger1, Michael Rodamer2, Thalia Erbes3, Hans Neubauer4, Bernd Kammerer1*

1 Center for Biological Systems Analysis ZBSA, Albert-Ludwigs-University Freiburg, 79104 Freiburg, Germany
2 Agilent Technologies, Waldbronn, Germany
3 Institute of Biology II, Albert-Ludwigs-University Freiburg, 79104 Freiburg, Germany
4 University Medical Center Freiburg, 79106 Freiburg, Germany
5 University Medical Center Freiburg, 79106 Freiburg, Germany

Abstract

Metabolomics deals with analysis of highly complex biological samples resulting in insufficient separation of relevant metabolites from matrix substances with one-dimensional liquid chromatography. Comprehensive two-dimensional liquid chromatography (2D-LC) is a promising technique for the analysis of complex samples because of its increased peak capacity. Comprehensive 2D-LC-MS/MS has been applied for a targeted metabolomics approach regarding metabolites from RNA catabolism. Combination of a Zorbax Eclipse Plus C18 column with a Zorbax Bonus-RP column resulted in increased peak capacity, minimisation of matrix effects and excellent reproducibility.

Keywords: Comprehensive 2D-LC; Metabolomics; Mass spectrometry

Introduction

The emerging field of metabolomics often deals with the analysis of highly complex matrices. Consequently, not only a capable mass spectral analysis for identification of metabolites but also a high chromatographic performance is indispensable for metabolomics studies. Therefore, new methods have to achieve increased peak capacity and reduced ion suppression in order to optimize separation power and minimize interferences between analytes. Typical metabolomics applications are often characterized by large numbers of similar analytes, which are neither easy to separate, nor too different in structure or size formula. Therefore, it is highly required to separate them to achieve best qualitative and quantitative results. Due to similarity of many analytes, it is a challenging task to realise powerful LC separation as one dimensional LC often compromises separation of similar compounds. Comprehensive 2D-LC is the ideal tool for the analysis of complex matrices such as urinary samples. The concept of comprehensive 2D-LC is depicted in Figure 1, the transformation of chromatograms resulting from second dimension separation into a 2D-LC chromatogram in Figure 2. The main task in 2D-LC method development is to maximize peak capacity of two different separation techniques such as reversed phase and normal phase LC, while maintaining the possibility to couple these two dimensions. In theory, peak capacity of comprehensive 2D-LC separations can be estimated by multiplication of peak capacities of first and second separation dimension [1]. The multiplicity of 2D separations can be explained by the following equation:

\[
\text{n}_{2D} = n_1 \times n_2
\]

In this equation \(n_1\) is the peak capacity of the 2D separation. \(n_1\) represents the first dimension and \(n_2\) the second dimension peak capacities. In practice theoretical peak capacity is often constricted by incomplete orthogonality and undersampling. Aiming towards a maximum peak capacity, the applied separation mechanisms should be independent and peaks should be equally distributed in the 2D separation space [2]. If the separation mechanisms of the first and second chromatographic dimension show no correlation, the separation is highly orthogonal. There are different concepts to theoretically assess the orthogonality of a two dimensional separation [3-5], which can be applied for evaluation of different separation mechanisms during method development. Gilar et al. [4] developed the following equation for calculation of orthogonality based on plotting a 2D separation space and spotting data points into rectangular bins:

\[
\sigma = \frac{\sum \text{bins} - \sqrt{\text{P(max)}}}{0.63 \text{P(max)}}
\]

P(max) is the total number of bins and \(2\text{bins}\) is the number of bins occupied by data points. Highest orthogonality is reached at a surface coverage of normalized separation space of 63%, lowest orthogonality at 10%. Another approach to evaluate orthogonality of a 2D separation space is based on the entropy H. With X and Y as the two dimensions of a separation, the following equation has been developed [5]:

\[
O_{XY} = \frac{\text{H}(Y|X)}{\text{H}(Y)} \times 100
\]

If the separation system is nonorthogonal, \(H(Y|X)\) is equal to zero. In contrast, if the separation system is fully orthogonal, \(H(Y|X)\) is equal to \(H(Y)\). Nevertheless, no agreement has been attained relating to the ideal method to calculate orthogonality. Consequently, not only different stationary and mobile phases but also pH values, gradients and modifier effects have to be evaluated during method development. Besides the possible issues with the miscibility of solvents, flow rates and timing of the ultra short analysis in the second dimension have

*Corresponding author: Bernd Kammerer, Center for Biosystem Analysis, Albert-Ludwigs-University, Freiburg, Habsburgerstraße 49, 79104 Freiburg, Germany, Tel: 0761-203-97137; Fax: 0761-203-97177; E-mail: Bernd.Kammerer@zbsa.uni-freiburg.de

Received August 21, 2015; Accepted August 27, 2015; Published September 10, 2015

Citation: Willmann L, Schlimpert M, Pan D, Bauer C, Trafkowski J, et al. (2015) Comprehensive Two-Dimensional Liquid Chromatography in Metabolome Analysis. J Chromatogr Sep Tech 6: 288. doi:10.4172/2157-7064.1000288

Copyright: © 2015 Willmann L, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
to be optimized [6]. Especially, the sampling time is essential for 2D-LC because of its effect on resolution. As short sampling times usually leads to better resolution, each first dimension peak should be sampled three to four times into the second dimension [7]. In consideration of the wide concentration range of metabolites in biological samples, choosing the optimal sampling time can be challenging.

Materials and Methods

For 2D-LC-MS/MS experiments, following instrumentation was applied [8]: 1290 Infinity Quaternary Pump (G4204A), 1290 Infinity Binary Pump (G4220A), 1290 Infinity Autosampler (G4226A), 1290 Thermostat (G1330B), 1290 Infinity Valve Drive (G1170A) with 2pos/4-port Duo Valve (Figure 3), 6460 triple quadrupole mass spectrometer.

Figure 1: Concept of comprehensive 2D-LC [12].

Figure 2: Transformation of chromatograms from second dimension separation into a 2D-LC chromatogram [12].
(Agilent, Waldbronn, Germany) equipped with electrospray ionization source (Agilent Jet Stream).

Final chromatographic gradient (1D): 0-20 min, 2% B; 20-45 min; 2-30% B; 45-65 min, 30% B; 65-75 min, 50-75% B; 75-90 min, 75% B; 90.1 min, 2% B.

Following MS settings were applied: capillary voltage, 4000 V; nozzle voltage, 500 V; gas temperature, 300°C (7 l/min); sheath gas, 350°C (7 l/min); nebulizer pressure, 50 psi. Positive ionization mode was applied with a step size of 0.1 amu, threshold of 0 and cell accelerator voltage of 7 V at centroid data storage.

For data acquisition and post processing following software was applied: Agilent MassHunter Workstation Data Acquisition B.04.01; Agilent OpenLab CDS ChemStation 2D LC A.01.05; Agilent MassHunter Qualitative Analysis B.04.00; LCxLC-HRMS Version 2.4b2 (GC Image, Lincoln, Nebraska, USA); Interface Suite™ v 4.11 (United States Environmental Protection Agency, Washington, DC, USA).

Results and Discussion

Modified nucleosides from RNA metabolism can occur in different, highly complex biological matrices, e.g. urine [9], blood [10], cell culture supernatants [11]. Consequently, we have established a 2D-LC method coupled to a triple quadrupole mass spectrometer, aiming towards maximization of peak capacity and minimization of matrix effects. We have analysed different urinary samples of healthy volunteers which have been prepurified by application of phenylboronic acid affinity chromatography [11] resulting in purification of cis-diols. In 2D-LC analysis the effluent from the first chromatographic dimension was alternately transferred to two identical 80 µl loops and further analysed on the second dimension column (Figure 3). Alternate loop filling was achieved by switching the 2-position/4-port valve. Combination of an Eclipse Plus C18 (150 × 2.1 mm, 1.8 µm) in the first and a Zorbax Eclipse XDB-C18 (50 × 3 mm, 1.8 µm) in the second dimension (Figure 4a) lead to an additional separation of some target compounds (Box in Figure 4a) and separation of numerous matrix substances. Aiming towards enhanced orthogonality of separation, we combined a Zorbax SB-Aq (100 × 2.1, 3.5µm) and Zorbax Bonus-RP (50 × 3 mm, 1.8 µm pore size) column as a combination with more different chromatographic selectivity. We observed an increased separation in the second dimension (Box in Figure 4b), but still an inadequate overall peak capacity. In order to increase the separation in the second dimension we aimed towards minimization of the injection volume from the first chromatographic dimension onto the second dimension in relation to the second dimension column volume which is crucial in 2D-LC. This can be realized either by choosing a lower solvent flow in the first dimension or a higher second dimension column volume. To achieve this goal, we coupled the Eclipse Plus C18 (150 × 2.1 mm, 1.8 µm) with a Zorbax Bonus-RP (50 × 4.6 mm, 1.8 µm) in the second chromatographic dimension. For the second dimension we applied shifted gradients with an analysis time of 54 s at high flow rate (2.5 ml/min). Altogether, we detected up to 29 compounds from RNA metabolism and cross-linked pathways in urinary samples (Figure 5). Detection has been executed in full scan, neutral loss scan and multiple reaction monitoring. Exemplary, the MS/MS spectrum of N6-Threonyl-carbamoyladenosine is depicted in Figure 6. Application of 2D-LC-MS/MS has shown increased peak capacity and adequate reproducibility in repeated measurements. Eventually, application of 2D-LC has great potential for metabolomics in due consideration adequate column orthogonality and dimensions.
Table 1: Compound setup.

| Peak No. (Figure 2a) | Peak No. (Figure 2b) | Peak No. (Figure 3) | Compound | Formula | [M+H]+ [m/z] | MRM transitions (Quantifier / Qualifiers) [m/z] | Frag-moment [V] | Collision Potential [V] |
|---------------------|----------------------|---------------------|----------|----------|-------------|-----------------------------------------------|----------------|------------------------|
| 1                   | 1                    | 1                   | 1-Ribosyl-imidazolonicotinamide | C_{17}H_{15}N_{4}O_{7} | 255.1 | 123.1 / 106.1, 80.1, 78.1 | 100 | 10 / 20, 40, 40 |
| 2                   | 2                    | 2                   | 1-Ribosylimidazole-4-acetic acid | C_{16}H_{15}N_{3}O_{4} | 259.2 | 127.1 / 109.1, 81.1, 54.1 | 100 | 10 / 30, 40, 50 |
| 3                   | 3                    | 3                   | 5,6-Dihydouridine | C_{10}H_{13}N_{3}O_{3} | 247.2 | 115.2 / 97.1, 73.2, 55.2 | 70 | 5 / 17, 17, 25 |
| 4                   | 4                    | 4                   | Cytidine | C_{10}H_{13}N_{3}O_{3} | 244.2 | 112.2 / 95.1, 69.2, 67.2 | 80 | 5 / 45, 41, 60 |
| 5                   | 5                    | 5                   | Pseudouridine | C_{10}H_{13}N_{3}O_{3} | 245.2 | 209.2 / 155.2, 125.1, 82.1 | 100 | 4 / 5, 13, 29 |
| 6                   | 6                    | 6                   | 3-Methylcytidine | C_{10}H_{13}N_{3}O_{3} | 258.2 | 126.1 / 109.1, 95.1, 66.1 | 100 | 10 / 40, 40, 60 |
| 7                   | 7                    | 7                   | 1-Methylenosine | C_{10}H_{13}N_{3}O_{3} | 282.2 | 150.2 / 123.2, 108.2, 94.2 | 110 | 13 / 45, 60, 45 |
| 8                   | 8                    | 8                   | 3-(3-Amino-carboxypropyl)uridine | C_{18}H_{25}N_{4}O_{4} | 346.2 | 214.1 / 197.1, 168.1, 113.1 | 100 | 10 / 20, 40, 40 |
| 9                   | 9                    | 9                   | 5-Aminimidazol-4-carboxamid | C_{19}H_{23}N_{4}O_{5} | 259.2 | 127.2 / 110.1, 82.2, 55.2 | 80 | 5 / 21, 49, 60 |
| 10                  | 10                   | 10                  | Uracil | C_{5}H_{4}N_{3}O | 245.2 | 113.1 / 96.1, 70.1, 57.1 | 70 | 9 / 33, 33, 25 |
| 11                  | 11                   | 11                  | Guanosine | C_{10}H_{10}N_{4}O_{5} | 284.2 | 152.2 / 135.1, 110.1, 55.1 | 70 | 9 / 41, 41, 60 |
| 12                  | 12                   | 12                  | 1-Ribosyl-pyridin-2-one-5-carboxamide | C_{18}H_{18}N_{4}O_{6} | 271.2 | 139.1 / 122.1, 94.1 | 100 | 10 / 30, 60 |
| 13                  | 13                   | 13                  | Adenosine | C_{10}H_{10}N_{4}O_{5} | 268.2 | 136.4 / 119.4, 94.3, 92.3 | 100 | 13 / 49, 49, 60 |
| 14                  | 14                   | 14                  | Isoguanosine (ISTD) | C_{10}H_{10}N_{4}O_{5} | 284.2 | 152.2 / 135.1, 107.1, 57.2 | 110 | 13 / 41, 57, 33 |
| 15                  | 15                   | 15                  | Inosine | C_{10}H_{10}N_{4}O_{5} | 269.2 | 137.3 / 119.2, 110.2, 55.3 | 60 | 4 / 45, 45, 68 |
| 16                  | 16                   | 16                  | 1-Ribosyl-pyridin-3-one-4-carboxamide | C_{18}H_{18}N_{4}O_{6} | 271.2 | 139.1 / 122.1, 94.1 | 100 | 10 / 30, 60 |
| 17                  | 17                   | 17                  | 1-Methylguanosine | C_{12}H_{15}N_{5}O_{5} | 298.2 | 166.2 / 149.1, 135.1, 110.1 | 100 | 9 / 41, 45, 49 |
| 18                  | 18                   | 18                  | Thymine | C_{5}H_{4}N_{2}O | 285.2 | 153.2 / 136.1, 57.2, 55.2 | 60 | 4 / 33, 25, 25 |
| 19                  | 19                   | 19                  | 1-Methylthymine | C_{5}H_{4}N_{2}O | 283.2 | 151.1 / 110.1, 94.1, 82.1 | 80 | 10 / 40, 40, 50 |
| 20                  | 20                   | 20                  | N'-7-Thymineguanosine | C_{14}H_{12}N_{5}O_{6} | 326.2 | 194.2 / 149.1, 124.1, 55.2 | 70 | 9 / 45, 45, 68 |
| 21                  | 21                   | 21                  | N'-6-Dimethyladenosine | C_{10}H_{12}N_{5}O_{6} | 282.2 | 150.2 / 123.2, 94.2, 57.2 | 130 | 13 / 49, 49, 45 |
| 22                  | 22                   | 22                  | N'-Methylguanosine | C_{10}H_{12}N_{5}O_{6} | 298.2 | 166.2 / 149.1, 110.1, 57.2 | 90 | 9 / 37, 45, 60 |
| 23                  | 23                   | 23                  | N'-5-Acetylcytidine | C_{10}H_{12}N_{5}O_{6} | 286.2 | 154.1 / 112.1, 95.1, 69.1 | 80 | 5 / 25, 57, 53 |
| 24                  | 24                   | 24                  | N'-N'-Dimethylguanosine | C_{12}H_{14}N_{6}O_{8} | 312.2 | 180.1 / 135.1, 110.1, 46.1 | 100 | 10 / 40, 40, 40 |
| 25                  | 25                   | 25                  | N'-Succinyladenosine | C_{12}H_{14}N_{6}O_{8} | 384.2 | 252.1 / 162.1, 136.1, 119.1 | 100 | 10 / 40, 30, 60 |
| 26                  | 26                   | 26                  | 5-Deoxy-5-methylthioadenosine | C_{12}H_{14}N_{6}O_{8} | 298.2 | 136.2 / 119.1, 75.2, 61.2 | 90 | 13 / 57, 33, 33 |
| 27                  | 27                   | 27                  | N'-Threonyl-carbamoyladenosine | C_{14}H_{18}N_{7}O_{8} | 413.2 | 281.1 / 162.1, 136.1, 119.1 | 100 | 10 / 20, 30, 60 |
| 28                  | 28                   | 28                  | N'-Methyl-N'-threonylcarbamoyladenosine | C_{14}H_{18}N_{7}O_{8} | 427.3 | 295.1 / 150.1, 94.1 | 100 | 5 / 25, 60 |
| 29                  | 29                   | 29                  | 2-Methylthio-N'-threonylcarbamoyladenosine | C_{14}H_{18}N_{7}O_{8} | 459.2 | 327.1 / 208.1, 182.1, 134.1 | 100 | 10 / 30, 30, 60 |
Conclusion

The developed 2D-LC-MS/MS method enabled the separation of numerous analytes, which can easily interfere with each other and enabled the identification of all target substances in a single run. The additional separation reduces interferences and allows a stable robust analysis for investigation of metabolic signatures.

References

1. Giddings JC (1987) Concepts and comparisons in multidimensional separation. Journal of High Resolution Chromatography 10:319-323.
2. Wankat PC (1992) Unified separation science. By J. Calvin Giddings, Wiley, New York, 320 pp., 1991. AIChE Journal 38:1303-1303.
3. Liu Z, Patterson DG, Lee ML (1995) Geometric Approach to Factor Analysis for the Estimation of Orthogonality and Practical Peak Capacity in Comprehensive Two-Dimensional Separations. Analytical Chemistry 67:3840-3845.
4. Gilar M, Olivova P, Daly AE, Gebler JC (2005) Orthogonality of separation in two-dimensional liquid chromatography. Anal Chem 77: 6426-6434.
5. Pourhaghighi MR, Karzand M, Girault HH (2011) Orthogonality of two-dimensional separations based on conditional entropy. Anal Chem 83: 7676-7681.
6. Li D, Jakob C, Schmitz O (2015) Practical considerations in comprehensive two-dimensional liquid chromatography systems (LCxLC) with reversed-phases in both dimensions. Anal Bioanal Chem 407: 153-167.
7. Murphy RE, Schure MR, Foley JP (1998) Effect of Sampling Rate on Resolution in Comprehensive Two-Dimensional Liquid Chromatography. Analytical Chemistry 70:1585-1594.
8. Willmann L, Erbes T, Krieger S, Trafkowski J, Rodamer M, et al. (2015) Metabolome analysis via comprehensive two-dimensional liquid chromatography: identification of modified nucleosides from RNA metabolism. Anal Bioanal Chem 407: 3555-3566.
9. Bullinger D, Fux R, Nicholson G, Plontke S, Belka C, et al. (2008) Identification of urinary modified nucleosides and ribosylated metabolites in humans via combined ESI-FTICR MS and ESI-IT MS analysis. J Am Soc Mass Spectrom 19: 1500-1513.
10. Colonna A, Russo T, Esposito F, Salvatore F, Cirimino F (1983) Determination of pseudouridine and other nucleosides in human blood serum by high-performance liquid chromatography. Anal Biochem 130: 19-26.
11. Willmann L, Erbes T, Halbach S, et al. (2015) Exometabolom analysis of breast cancer cell lines. Metabolic signature. Sci Rep 5: 13374.
12. Carr PW, Stoll DR (2015) Two-Dimensional Liquid Chromatography - Principles, Practical Implementation and Applications. Germany: Agilent Technologies.